Character Biosciences has secured $93 million in Series B funding to support two clinical trials for its treatments in dry age-related macular degeneration. The financing was co-led by new investors aMoon and Luma Group.
Mar 25, 2025•9 months ago
Amount Raised
$93 Million
Round Type
series b
Investors
Luma GroupA Moon
Description
Character Biosciences is entering clinical trials with substantial company-generated human data to inform its treatments for dry age-related macular degeneration. The $93 million funding round will help achieve clinical proof of concept for its lead programs. The Series B financing, announced recently, was co-led by aMoon and Luma Group. Based in Jersey City, New Jersey, Character aims to address a significant patient population affected by AMD.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech